Board of Directors

Wayne B. Weisman

Chairman of the Board

Wayne B. Weisman has been a director of the company and the chairman of our board since 2008. Since 2007, Weisman has been a director of the corporate general partner of the common general partner of SCP Vitalife, which beneficially owns 33.6% of our outstanding stock as of April 1, 2016. He has also served as a managing member of SCP Vitalife Management Company, LLC, which by contract provides certain management services to the common general partner of SCP Vitalife.

He has also led the activities of SCP Private Equity Partners II, L.P., a venture capital fund of which he and Churchill are principals in the life sciences area. His activities include investments in the United States and Israel. He has also led several other technology investments for SCP Private Equity Partners II, L.P. He has been a member of the investment committee of the Vitalife Life Sciences funds since their inception in 2002 and has worked closely with these funds since then.

Weisman has been a member of the board of directors of CIP Capital L.P., a small business investment company licensed by the U.S. Small Business Administration since its inception in 1991. From 1992 to 1994, Weisman was executive vice president and member of the board of directors of a public drug delivery technology company. In addition, he also operated a management and financial advisory firm focusing on the reorganization and turnaround of troubled companies and began his career practicing reorganization law at a large Philadelphia law firm.

Weisman possesses extensive experience in venture capital investing, particularly in the life sciences area. Weisman serves on the board of ReWalk Robotics Ltd. and on a number of private company boards including the boards of DIR Technologies, Endospan Ltd., Ivenix, LLC, and Echo360, Inc. He is the chairman of the boards of trustees of Young Scholars School, Young Scholars Frederick Douglass, and Young Scholars Kenderton. He is also an advisory board member of the Philadelphia-Israel Chamber of Commerce and Mid-Atlantic Diamond Ventures, the venture forum of Temple University. Weisman holds a B.A. from the University of Pennsylvania, and a J.D. from the University of Michigan Law School.

As a long time director of our company, Weisman’s extensive knowledge of our business and history, experience as a board member of multiple publicly traded and privately held companies, and expertise in developing, financing, and providing strong executive leadership to numerous growing life science companies contributed to our board’s conclusion that he should serve as a director of our company.

William L. Ashton

Director

William L. Ashton has been a director of the company since 2009. Since the beginning of 2013, Ashton has been a principal at Harrison Consulting Group, Inc., a privately held biopharmaceutical consulting firm. From August 2009 to June 2013, Ashton was the senior vice president of external affairs reporting to the president and an assistant professor at the University of the Sciences in Philadelphia, Pennsylvania. From August 2005 to August 2009, Ashton was the founding dean of the Mayes College of Healthcare Business and Policy.

Ashton has 29 years of experience in the biopharmaceutical industry. From 1989 to 2005, Ashton held a number of positions at Amgen Inc., a biotechnology company, including vice president of U.S. sales and vice president of commercial and government affairs. Ashton currently serves on the boards of directors of Galena Biopharma, Inc. and Sucampo Pharmaceuticals, Inc. He is also a member of the board of directors of the National Osteoporosis Foundation and Friends of the National Library of Medicine at the National Institutes of Health. Ashton holds a B.S. in education, from the California University of Pennsylvania and an M.A. in education from the University of Pittsburgh.

Ashton’s extensive experience with pharmaceutical and biological products’ commercialization and reimbursement issues, his past advisory role during the early years of Auxilium, as well as his experience as a board member of privately held companies and his scientific expertise contributed to our board’s conclusion that he should serve as a director of our company.

Michael Berelowitz, M.D.

Director

Michael Berelowitz was elected to our board in March 2014 upon the consummation of our IPO. Since 2011, Berelowitz has served as a biopharmaceutical consultant. From 2009 to 2011, Berelowitz was senior vice president and head of clinical development and medical affairs in the specialty care business unit at Pfizer, Inc., a pharmaceutical company. From 1996 to 2009, he held various other roles at Pfizer, Inc., beginning as a medical director in the diabetes clinical research team and then assuming positions of increasing responsibility.

Prior to that, Berelowitz spent a number of years in academia. Berelowitz also serves on the board of directors of Oramed Pharmaceuticals Inc. Among his public activities, Berelowitz has served on the board of directors of the American Diabetes Association and the Clinical Initiatives Committee of the Endocrine Society, and has chaired the Task Force on Research of the New York State Council on Diabetes. He has also served on several editorial boards, including the Journal of Clinical Endocrinology and Metabolism and Endocrinology, Reviews in Endocrine and Metabolic Disorders, and Clinical Diabetes.

Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters in the areas of pituitary growth hormone regulation, diabetes, and metabolic disorders. Berelowitz holds adjunct appointments as professor of medicine in the divisions of endocrinology and metabolism at SUNY Stony Brook and Mt. Sinai School of Medicine in New York. Berelowitz’s years of experience in management roles in the pharmaceuticals industry, as well as his vast skill and expertise in the fields of endocrinology and diabetes, contributed to our Board’s conclusion that he should serve as a director of our company.

Winston J. Churchill

Director

Winston J. Churchill has been a director of the company since 2008. Since 2007, Churchill has been a director of the corporate general partner of the common general partner of SCP Vitalife, which beneficially owns 33.6% of our outstanding stock as of April 1, 2016. He has also served as a managing member of SCP Vitalife Management Company, LLC, which by contract provides certain management services to the common general partner of SCP Vitalife.

Churchill has also served since 1993 as the president of CIP Capital Management, Inc., the general partner of CIP Capital, L.P., an SBA-licensed private equity fund. Prior to that, Churchill was a managing partner of Bradford Associates, which managed private equity funds on behalf of Bessemer Securities Corporation and Bessemer Trust Company.

From 1967 to 1983, Churchill practiced law at the Philadelphia firm of Saul Ewing, LLP, where he served as chairman of the banking and financial institutions department, chairman of the finance committee, and was a member of the executive committee. Churchill is a director of Griffin Land & Nurseries, Inc., Innovative Solutions and Support, Inc., Amkor Technology, Inc., and various SCP Vitalife portfolio companies. In addition, he serves as a director on the boards of a number of charities and as a trustee of educational institutions including the Gesu School and Scholar Academies and is a trustee fellow of Fordham University.

From 1989 to 1993, Churchill served as chairman of the finance committee of the Pennsylvania Public School Employees’ Retirement System. He was awarded a B.S. in physics, summa cum laude, from Fordham University, followed by an M.A. in economics from Oxford University, where he studied as a Rhodes Scholar, and a J.D. from Yale Law School.

As a longtime director of our company, Churchill’s extensive knowledge of our business and history, experience as a board member of multiple publicly traded and privately held companies, and expertise in developing, financing, and providing strong executive leadership to numerous growing life science companies contributed to our Board’s conclusion that he should serve as a director of our company.

David Enloe, Jr.

President and Chief Executive Officer

David Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development, and GMP manufacturing. Most recently, he served as president and chief executive officer of Ajinomoto Bio-Pharma Services, a global, fully integrated CDMO.

Prior to joining Ajinomoto, Enloe served as head of Lonza’s Viral Therapeutics business unit, which was the result of Lonza’s acquisition of Vivante GMP Solutions, a gene therapy CDMO that he founded in June 2009 and where he served as president and CEO until its sale to Lonza AG. Under Enloe’s leadership, the business experienced rapid expansion, with revenues increasing 500% over a three-year period.

Preceding Vivante, Enloe spent 14 years with biotech company, Introgen Therapeutics, joining as its first employee in 1995 and serving as senior vice president and COO before being named president and CEO. Enloe served an integral role in taking the company through a successful IPO in 2020, as well as several other significant financial transactions. In addition, Mr. Enloe oversaw multiple large corporate and academic collaborations, as well as the filing of license applications with both the FDA and European regulatory authorities for Introgen’s lead product.

Enloe received a Bachelor of Business Administration, Accounting, from the University of Texas at Austin. He is a Certified Public Accountant and started his career in public accounting with Arthur Andersen & Co.

Gerri Henwood

Director

 

Bryan Reasons

Director

In his current roles as senior vice president of finance and chief financial officer of Impax Laboratories, Reasons’ responsibilities span accounting, financial planning and analysis, business development and investor relations, and corporate communications. Prior to joining Impax in 2012, Reasons held positions of increasing responsibility at Cephalon, Inc., where he successfully navigated acquisition by Teva Pharmaceutical Industries Ltd. for eight billion dollars. He previously served in a number of financial leadership roles at E.I. du Pont de Nemours and Company and PricewaterhouseCoopers LLP, ranging from corporate accounting, external reporting and audit, and business advisory services.

Reasons earned a bachelor’s degree in accounting from Pennsylvania State University and an MBA from Widener University. He is a certified public accountant.